GBA1-PD patients had a higher burden of motor complications than negative PD patients with comparable disease duration; these included dyskinesia (68% vs 42%, p 0.01, OR 3,95%IC 1.3–8.8), sleep problems including Rem Behavior Disorder RBD (75% vs 51%, OR 2.8, 95%IC 1.1–7.1, p 0.03) and any cognitive disturbances (64% vs 33%, OR 3.6, 95%IC 1.5–8.7 p 0.004). The gene discussed is GBA1; the disease is drug-induced dyskinesia.